Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Fate Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Fate Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $98.73M, down 14.9% year over year. For fiscal 2025 it was $107.83M, down 20.1% from the year before. Over ten years it grew 18.4% a year on average. The highest annual figure on record is $320.45M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $107.83M | -20.1% |
| FY2024 | Dec 31, 2024 | $135.00M | -21.8% |
| FY2023 | Dec 31, 2023 | $172.60M | -46.1% |
| FY2022 | Dec 31, 2022 | $320.45M | +48.7% |
| FY2021 | Dec 31, 2021 | $215.52M | +71.6% |
| FY2020 | Dec 31, 2020 | $125.62M | +43.1% |
| FY2019 | Dec 31, 2019 | $87.77M | +56.7% |
| FY2018 | Dec 31, 2018 | $56.02M | +63.1% |
| FY2017 | Dec 31, 2017 | $34.36M | +29.9% |
| FY2016 | Dec 31, 2016 | $26.45M | +33.2% |
| FY2015 | Dec 31, 2015 | $19.86M | +20.8% |
| FY2014 | Dec 31, 2014 | $16.44M | +36.9% |
| FY2013 | Dec 31, 2013 | $12.01M | +0.1% |
| FY2012 | Dec 31, 2012 | $12.00M | +21.7% |
| FY2011 | Dec 31, 2011 | $9.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $24.22M | -6.3% |
| Q2 FY2026 | Jun 30, 2026 | $24.39M | -11.1% |
| Q1 FY2026 | Mar 31, 2026 | $24.70M | -15.2% |
| Q4 FY2025 | Dec 31, 2025 | $25.43M | -24.4% |
| Q3 FY2025 | Sep 30, 2025 | $25.84M | -25.4% |
| Q2 FY2025 | Jun 30, 2025 | $27.43M | -20.7% |
| Q1 FY2025 | Mar 31, 2025 | $29.14M | -9.3% |
| Q4 FY2024 | Dec 31, 2024 | $33.61M | +5.6% |
| Q3 FY2024 | Sep 30, 2024 | $34.65M | +1.1% |
| Q2 FY2024 | Jun 30, 2024 | $34.60M | -15.3% |
| Q1 FY2024 | Mar 31, 2024 | $32.14M | -51.0% |
| Q4 FY2023 | Dec 31, 2023 | $31.82M | -63.5% |
| Q3 FY2023 | Sep 30, 2023 | $34.28M | -57.1% |
| Q2 FY2023 | Jun 30, 2023 | $40.88M | -49.7% |
| Q1 FY2023 | Mar 31, 2023 | $65.63M | -9.0% |
| Q4 FY2022 | Dec 31, 2022 | $87.19M | +25.4% |
| Q3 FY2022 | Sep 30, 2022 | $79.82M | +50.2% |
| Q2 FY2022 | Jun 30, 2022 | $81.31M | +69.3% |
| Q1 FY2022 | Mar 31, 2022 | $72.14M | +60.8% |
| Q4 FY2021 | Dec 31, 2021 | $69.52M | +78.3% |
| Q3 FY2021 | Sep 30, 2021 | $53.13M | +73.1% |
| Q2 FY2021 | Jun 30, 2021 | $48.02M | +80.1% |
| Q1 FY2021 | Mar 31, 2021 | $44.85M | +53.2% |
| Q4 FY2020 | Dec 31, 2020 | $38.98M | +54.6% |
| Q3 FY2020 | Sep 30, 2020 | $30.69M | +32.3% |
| Q2 FY2020 | Jun 30, 2020 | $26.67M | +23.3% |
| Q1 FY2020 | Mar 31, 2020 | $29.28M | +65.2% |
| Q4 FY2019 | Dec 31, 2019 | $25.21M | +78.9% |
| Q3 FY2019 | Sep 30, 2019 | $23.20M | +70.1% |
| Q2 FY2019 | Jun 30, 2019 | $21.63M | +28.6% |
| Q1 FY2019 | Mar 31, 2019 | $17.73M | +54.5% |
| Q4 FY2018 | Dec 31, 2018 | $14.10M | +42.6% |
| Q3 FY2018 | Sep 30, 2018 | $13.64M | +59.0% |
| Q2 FY2018 | Jun 30, 2018 | $16.82M | +112.1% |
| Q1 FY2018 | Mar 31, 2018 | $11.48M | +44.1% |
| Q4 FY2017 | Dec 31, 2017 | $9.89M | +58.7% |
| Q3 FY2017 | Sep 30, 2017 | $8.58M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.93M | – |
| Q1 FY2017 | Mar 31, 2017 | $7.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.23M | – |
See a number that looks wrong?